SCHEMBL559916

SCHEMBL559916

O=[C]C=Cc1ccccc1C(=O)NO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MPO P05164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC8 Q9BY41 6/20 0.43
MMP3 P08254 2/20 0.43
LMNA P02545 1/20 0.42
HDAC1 Q13547 6/20 0.40
LIG1 P18858 1/20 0.40
CAPN1 P07384 1/20 0.39
HDAC6 Q9UBN7 5/20 0.38
HDAC3 O15379 3/20 0.38
HDAC2 Q92769 3/20 0.38
HDAC7 Q8WUI4 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
IDO1 P14902 1/20 0.38
ALOX15 P16050 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11795899 0.85 GAA (0.57) GAAKDM4EMPOSMN1; SMN2HIF1A
SCHEMBL6645824 0.85 GAA (0.47) GAALMNACAPN1
SCHEMBL7664513 0.82 ALDH1A1 (0.53) KDM4ESMN1; SMN2LMNAHSD17B10
SCHEMBL7670365 0.82 CAPN1 (0.34) KDM4ELMNALIG1CAPN1HSD17B10
SCHEMBL7662720 0.82 CAPN1 (0.34) KDM4ESMN1; SMN2HDAC8LMNAHDAC1
SCHEMBL7664107 0.81 KEAP1 (0.47) GAAKDM4ESMN1; SMN2HIF1ACAPN1
SCHEMBL7661318 0.81 CAPN1 (0.36) KDM4ECAPN1CA1CA9HSD17B10
SCHEMBL7661570 0.81 HTT (0.38) GAAKDM4ECAPN1BACE1
SCHEMBL6958820 0.81 ALDH1A1 (0.43) KDM4ESMN1; SMN2LMNACAPN1
SCHEMBL6974613 0.81 L3MBTL1 (0.43) CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107410317-A Improve the diffusible wet tissue composition in wet tissue fabric and the wet tissue containing said composition 明进新科技股份有限公司 2017-12-01 CN claimed
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC 2011-11-24 US claimed
WO-2008011074-A2 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC (US) 2008-01-24 WO claimed
US-7312247-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2007-12-25 US claimed
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid ERRANT GENE THERAPEUTICS, LLC 2007-02-15 US claimed
EP-1408946-A4 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2004-06-09 EP claimed
EP-1408946-A2 HISTONE DEACETYLASE INHIBITORS Circagen Pharmaceutical (US) 2004-04-21 EP claimed
US-20020143052-A1 Histone deacetylase inhibitors ANGELA CHEN SABELLA 2002-10-03 US claimed
WO-2002076941-A2 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2002-10-03 WO claimed
CN-116617213-A Cinnamoyl mycoins and their use in the treatment of bacterial infections 西安世颂科技有限公司 2023-08-22 CN disclosed
CN-107410317-A Improve the diffusible wet tissue composition in wet tissue fabric and the wet tissue containing said composition 明进新科技股份有限公司 2017-12-01 CN disclosed
US-8420698-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2013-04-16 US disclosed
US-8262634-B1 Absorbent article having barrier sheet against the migration of the skin care composition THE PROCTER & GAMBLE COMPANY (US) 2012-09-11 US disclosed
US-20120035257-A1 Histone Deacetylase Inhibitors ERRANT GENE THERAPEUTICS, LLC 2012-02-09 US disclosed
WO-2000069482-A1 ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed
WO-2000069481-A1 ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed
WO-2000069483-A1 ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed
WO-2000069484-A1 ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed
WO-2000069485-A1 ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2000-11-23 WO disclosed
WO-1999045973-A1 DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR THE PROCTER & GAMBLE COMPANY (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035257-A1 Histone Deacetylase Inhibitors HDAC1, HDAC11, HDAC9 GAA 130/4885KDM4E 1526/4885MPO 2299/4885
US-20020143052-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC9 GAA 127/4885KDM4E 1581/4885MPO 2172/4885
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC6, HDAC5 GAA 83/4885KDM4E 1872/4885MPO 3013/4885
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid HDAC5, HDAC1, ZNF277 GAA 140/4885KDM4E 2444/4885MPO 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.